微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 59.5% | -14.48% | -3.98% | 49/159 | 48.66% | 恩华药业 | 71.67% | 行业排名> |
| 2026-03-31 | 61.97% | -11.74% | -1.08% | 50/159 | 50.28% | 海创药业 | 97.34% | 行业排名> |
| 2025-12-31 | 62.64% | -7.45% | -8.5% | 43/159 | 50.37% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 68.46% | -1.23% | -1.59% | 35/159 | -2.12% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 69.57% | 3.35% | -0.91% | 34/159 | 15.05% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 70.2% | 4.37% | 3.72% | 30/159 | 31.79% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 67.68% | 11.01% | -2.36% | 38/159 | 51.61% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 69.32% | 14.22% | 2.97% | 32/159 | 22.43% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 67.32% | 16.9% | 0.08% | 35/159 | 32.96% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 67.26% | 20.25% | 10.32% | 33/159 | 51.47% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 60.97% | 5.9% | 0.46% | 50/159 | 51.31% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 60.69% | 12.87% | 5.39% | 52/159 | 32.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 57.59% | 9.31% | 2.95% | 62/159 | 38.22% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 55.93% | 3.15% | -2.85% | 64/159 | 52.66% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 57.57% | 3.26% | 7.08% | 66/159 | 53.51% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 53.77% | -4.72% | 2.06% | 72/159 | 5.67% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 52.68% | -6.37% | -2.85% | 75/159 | 20.91% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 54.23% | -8.51% | -2.75% | 72/159 | 54.06% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 55.76% | -4.14% | -1.19% | 72/159 | 54.9% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 56.43% | 3.38% | 0.29% | 61/159 | 46.49% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 56.26% | -2.56% | -5.07% | 67/159 | 46.97% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 59.27% | 7.64% | 1.9% | 53/159 | 53.79% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 58.16% | 8.99% | 0.74% | 62/159 | -147.51% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 57.74% | -3.76% | 8.19% | 54/159 | 53.85% | 首药控股 | 99.94% | 行业排名> |
| 2019-12-31 | 53.37% | -11.18% | -2.23% | 69/159 | -1232.76% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-09-30 | 54.58% | -15.69% | -9.02% | 54/159 | 54.86% | 微芯生物 | 95.14% | 行业排名> |
| 2019-06-30 | 60% | -8.43% | 8.96% | 48/159 | 54.88% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-03-31 | 55.06% | -17.47% | -8.36% | 53/159 | 50.75% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | 60.09% | -2.5% | -7.19% | 52/159 | -210.26% | 微芯生物 | 96.09% | 行业排名> |
| 2018-09-30 | 64.74% | 2% | -1.19% | 28/159 | 53.75% | 微芯生物 | 96.11% | 行业排名> |
| 2018-06-30 | 65.52% | 17.71% | -1.8% | 27/159 | 53.16% | 微芯生物 | 95.5% | 行业排名> |
| 2018-03-31 | 66.72% | 2% | 8.26% | 28/159 | 53.78% | 微芯生物 | 96.27% | 行业排名> |
| 2017-12-31 | 61.63% | 26.37% | 10.72% | 40/159 | 52.25% | 贝达药业 | 95.47% | 行业排名> |
| 2017-06-30 | 55.66% | 504.65% | 14.14% | 36/159 | 47.61% | 贝达药业 | 95.51% | 行业排名> |
| 2016-12-31 | 48.77% | 2% | 429.76% | 51/159 | 48.17% | 贝达药业 | 95.54% | 行业排名> |
| 2016-06-30 | 9.21% | 2% | 2% | 88/159 | 45.93% | 贝达药业 | 95.74% | 行业排名> |